key: cord-0269003-o1hqz5nr
authors: Murayama, A.; Kamamoto, S.; Yamada, K.; Bhandari, D.; Shoji, I.; Mamada, H.; Kawashima, M.; Yamashita, E.; Saito, H.; Kusumi, E.; Sawano, T.; Sapkota, B.; Tanimoto, T.; Ozaki, A.
title: Pharmaceutical Payments to Japanese Board-certified Infectious Disease Specialists: A Four-year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
date: 2022-03-10
journal: nan
DOI: 10.1101/2022.03.09.22271972
sha: 72107ff1224ef2a671ceffdfca691f21a32880b8
doc_id: 269003
cord_uid: o1hqz5nr

Abstract Objective Conflict of interest with pharmaceutical companies is one of the most contentious issues in infectious diseases. However, there is a lack of whole picture of detailed payments in Japan. Study Design and Setting This retrospective study assessed financial relationships between pharmaceutical companies and all infectious disease specialists board-certified by the Japanese Association for Infectious Disease, using publicly disclosed payment data from 92 pharmaceutical companies. Descriptive analyses were conducted for the payments. Payment trends were examined by the generalized estimating equations. Results Of 1614 board-certified infection disease specialists, 1,055 (65.4%) received a total of $17,784,070 payments, corresponding to 21,680 instances between 2016 and 2019. The mean (SD) and median (IQR) were $16,857 ($45,010) and $3,183 ($938-$11,250) in payments. All board executive members of Japanese Association for Infectious Diseases received higher payments averaging $163,792. There were no significant changes in payments per specialist (annual change rate: -1.4% [95% CI: -4.7- 2.3%], p=0.48) and prevalence of specialists with payments (annual change rate: -1.4% [95% CI: -3.1-0.2%], p=0.093) over the four years. Conclusion There were substantial financial relationships between pharmaceutical companies and board-certified infectious disease specialists in Japan. Such personal payments must be restricted to a certain level to avoid potential conflict of interest.

As of November 2021, the Association required physicians to complete several 1 4 1 requirements to certificate them as infectious disease specialists, such as being a 1 4 2 specialist certified by at least one of the 19 major Japanese medical societies [12] , medical license and at least three years of specialized training in infectious diseases at 1 4 5 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ;  1 1 an institution accredited by the Association, and having published at least one academic 1 4 6 article on a peer-review journal and at least two conference presentations as the first 1 4 7 author. The population-averaged generalized estimating equations (GEE) were performed to 2 0 0 evaluate the payment trends. As the payment distribution was highly skewed specialists with one or more payments, were reported as a relative percentage. As The Ethics Committee of the Medical Governance Research Institute approved this 2 2 3 study (approval number: MG2018-04-20200605; approval date: June 5, 2020). As this 2 2 4 study was a retrospective analysis of the publicly available information, informed 2 2 5 consent was waived by the Ethics Committee. We identified 1,614 infectious disease specialists certified by the Association as of 2 2 9

November 10, 2021. The Association stated that there were a total of 1,622 infectious 2 3 0 disease specialists in Japan, and therefore, names of eight specialists missing were not 2 3 1 disclosed on the webpage, as the specialists could have wished not to disclose their 2 3 2 names on the webpage. Overview and Per-Specialist Payments 2 3 5 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. in Mann-Whitney U test) over the four-year. The average annual payments per specialist ranged from $5,775 (SD: $13,410) in 2017 (724 out of 1614) in 2019, but were not statistically significant (p=0.12). Among 78 companies making payments, 10 companies were devoid of the four-year 2 6 9 continuous payment data. Excluding payments from ten companies, the specialists 2 7 0 received payments averaging from $5,562 (SD: $13,383) in 2017 to $6,105 (SD: 2 7 1 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The top companies made 63.8% of the total payments, representing $11,340,870 and (SD: $2,578) and 2.8 (SD: 1.9) cases, respectively. In short, each company made an 2 8 2 average of $2,333 payments, entailing 2.8 cases per specialist, to 74.9 specialists in 2 8 3 average for the reimbursement of lecturing, consulting and writing. Boehringer Ingelheim ($5,002), and AstraZeneca ($4,990) . Payment categories by each 2 8 9 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.09.22271972 doi: medRxiv preprint 1 specialists ($3,183 in median four-year combined payments and $1,430-$1,720 in 3 2 6 median single-year payments) were higher than all of the available evidence among Second, we found that the payment values and prevalence of specialists with payments companies did not decline nor increase, but remained stable for the last four years.

Although we found that there were many drugs newly approved or gained additional 3 4 1 indications for infectious diseases, the Japanese government now recommends 3 4 2 physicians to refrain from using new antibiotics to prevent antimicrobial-resistant 3 4 3 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. only on a small portion of the infectious disease specialists in Japan. Surprisingly, a Association and other medical societies. For example, the specialist with the largest The specialist with the second-largest payments ($421,678) was also in authoritative Welfare[7] and as a member of government scientific advisory committee. The specialist with the fourth largest payments ($318,565) was the former president of 3 6 1 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.09.22271972 doi: medRxiv preprint the Association who served from 2017 to 2020. He was also a current executive member 3 6 2 of the Association and the deputy chairperson of the Japanese government COVID-19 3 6 3 scientific advisory board, but his COI was not publicly disclosed by neither the The receipt of substantial personal payments by executive members of medical societies Diseases had much larger financial relationships with pharmaceutical companies over 3 7 8 the past several years, with 3.2 times higher median annual payments than those among 3 7 9

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. in several specialties. [3, 4, 23, 44] More transparency is required to reduce the undue 3 9 0 influences of financial relationships with pharmaceutical companies on physician 3 9 1 behaviors and potentially patients care, [28, 45] to increase trust in healthcare, and to payments to the specialists to a certain degree would be a simple and reasonable 3 9 7 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.09.22271972 doi: medRxiv preprint solution, but it is equally hard to implement by the professional medical societies when 3 9 8 many of the society board members and societies themselves are financially tied to This analysis has few limitations. As we previously noted, our manual collection of (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ; 2 6 many unavoidable confounders on the personal payments at individual specialist level.

However, our robust statistical analysis with GEE modeling has helped nullify effects of for prospective researchers to explore the same in other countries as well. The majority of the certified infectious disease specialists received substantial personal such as those in the executive board had stronger financial ties with the companies. Such personal payments must be restricted to a certain level to avoid potential conflict (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The authors thank the Tansa (formerly known as Waseda Chronicle) for providing 4 3 5 payment data. Also, we appreciate Mr. Souto Nagano, an undergraduate student from 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ; All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.09.22271972 doi: medRxiv preprint 4 0 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Drug price for vaccines was not determined and was open priced in Japan. So, it was not available.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Physicians with specific payments, n (%)